Development and Optimization of Solid Lipid Nanoparticle for Topical Delivery by Chaudhari, Pallavi M & Ghodake, Mahananda.V
Firdouse et el                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(5-s):105-121 
ISSN: 2250-1177                                                                                  [105]                                                                                 CODEN (USA): JDDTAO 
Available online on 18.10.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                            Research Article  
Development and Optimization of Solid Lipid Nanoparticle for Topical 
Delivery 
Chaudhari Pallavi M1*, Ghodake Mahananda.V2 
Department of Pharmaceutics, Dr. D.Y. Patil College of Pharmacy, Akurdi, Pune – 411044 
 
ABSTRACT  
The aim of present work was to develop and evaluate solid lipid nanoparticle (SLNs) based gel for topical delivery of anti-inflammatory drug. 
Material and method Nabumetone loaded SLNs were developed by hot homogenization followed by ultra- sonication technique using compritol 
888 ATO as solid lipid and tween 80 as a surfactant. Developed SLNs were evaluated for particle size, entrapment efficiency (EE) and drug 
release profile. Process and formulation parameters were optimized. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) 
studies were carried out on SLNs to mark the change in the drug and lipid modification. The Nabumetone based gels were prepared using 
carbopol 940 as gelling agent. Results and conclusion: The F14 batch had shown maximum entrapment efficiency up to 94.40 and sustained 
drug release for more than 7 hours. The particle size of optimized batch (F14) was found to be 16.54.  
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INTRODUCTION  
The skin structure of human skin is a complex structure that 
potentiates a major route for delivery of the drugs. Skin 
basically has two main layers – Epidermis and Dermis. The 
epidermis is the superficial layer of the skin and composed of 
stratified keratinised squamous epithelium that varies in 
thickness in different parts of the body. The major types of 
cells: keratinocytes, melanocytes, Langerhans cell, and 
merkel cells form the epidermis. The epidermis has following 
four layers, in most of the regions of the body (1). The stratum 
corneum is the outermost layer of the epidermis. The 
possible pathways of molecular penetration across the 
stratum corneum include intercellular, transcellular and 
appendagel. 
 Stratum Spinosum  
 Stratum Granulosum  
 Stratum Lucidum  
 Stratum Corneum  
 
 
 Figure No.1: Anatomy of human skin 
Dermis is the second layer of skin that is composed of 
connective tissues collagen and elastic fibres. In dermis 
blood vessels, nerves, glands and hair follicles are embedded. 
Dermis layer is divided into a papillary region and a reticular 
region, on the basis of tissue structure (2,3).  
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Rheumatoid arthritis is a form of arthritis, an autoimmune 
disease that causes pain, swelling, stiffness and loss of 
function in the joints and remains the most important form 
of arthritis seen in rheumatologically practice in the 
developed world. The geographical distribution of the 
disease is remarkably homogeneous. The causes of 
rheumatoid arthritis are still unclear and a wide variety of 
factors namely genes, environment and hormones are 
suspected to contribute. Recent years have seen considerable 
advances in our understanding of both the clinical and basic-
research aspects of rheumatoid arthritis.  Treatments include 
medicine, lifestyle changes and surgery. The signs and 
symptoms, include pain in the joints, swollen and tender 
joints, including joint inflammation, fatigue etc (4,5). 
Etiology    
The etiology of RA is not fully understood despite extensive 
study of metabolic and nutritional factors, the endocrine 
system, and geographic, psychological, and occupational 
data. This response supports the suspicion of an infectious 
origin of the disease process, which includes various bacteria 
and viruses, but without evidence of precipitating events. 
Even without this specific knowledge, treatment modalities 
have been developed that, while not curing the disease, can 
provide relief from the symptoms of the disease. Evidence 
points to a complex interplay between environmental and 
genetic factors. These and other regions of the Major 
Histocompatibility Complex may confer susceptibility to 
more severe disease by causing a specific arthrogenic 
peptide to be presented to CD4+ T cells. Scientists are now 
focusing on the idea that it is a T-cell-mediated autosomal 
disease precipitated by both genetic and environmental 
factors. The pharmacological treatment is done by analgesic, 
anti-inflammatory agents (6). 
Arthritis affects 15% people i.e. over 180 million people in 
India. Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
among the most prescribed medications for arthritis. As the 
use of oral NSAIDs possesses problems as not being patient 
friendly, cause various gastrointestinal adverse effects, so 
topical administration of these drugs is always the best 
choice since adverse effects occur commonly with systemic 
NSAID therapy (7). Transdermal delivery of nonsteroidal anti-
inflammatory drugs may be an interesting strategy for 
delivering these drugs to the diseased site. In recent years, 
solid lipid nanoparticles (SLN) have been used in topical 
drug formulations and are proven clinically as superior to 
plain drug topical therapy. Small particle size ensures close 
contact to the stratum corneum and drug encapsulated in 
lipid improves selective drug delivery to skin layers. SLN 
possess a solid matrix, which has the potential to modulate 
the drug release over a prolonged period of time with a 
reduced rate of systemic absorption (8).  
Solid Lipid Nanoparticles (SLNs) 
Solid Lipid Nanoparticles (SLN), which were first mentioned 
in 1991, are colloidal lipid carriers, solid at room and body 
temperature. SLN are obtained from GRAS (generally 
recognized as safe) lipids and surfactants, devoid of toxicity.   
SLN have been applied in the pharmaceutical industry for 
controlled drug release and increasing the bioavailability of 
trapped active substance by changing the dissolution rate in 
parenteral (intravenously, intramuscularly or 
hypodermically) oral and rectal therapies, in ophthalmology 
and in external uses (dermatology, cosmetics).SLN are 
considered promising carriers for active cosmetic 
ingredients due to many advantages over traditional forms. 
The SLNs have a number of features determining their 
eligibility as carriers for cosmetic purposes, such as: 
• Protection of unstable compounds against chemical 
degradations, e.g. retinoid.  
• Controlled active ingredient release.  
• The ability to function as occlusal complexes.  
• Exhibited potential as UV blockers.  
Structure and properties of solid lipid nanoparticles: SLN are 
composed of a core of solid lipid with bioactive material 
constituting a part of the lipid matrix. Such particle is 
stabilized by the surfactant layer or a mixture of surfactants 
(9).  
Advantages of SLN:  • Control and / or target drug release. 
 • Excellent biocompatibility • Improve stability of pharmaceuticals.  • High and enhanced drug content.  • Easy to scale up and sterilize.  • Better control over release kinetics of encapsulated 
compounds.  • Enhanced bioavailability of entrapped bioactive 
compounds.  • Chemical protection of labile incorporated compounds.  • Much easier to manufacture than biopolymeric 
nanoparticles. 
 • No special solvent required.  • Conventional emulsion manufacturing methods applicable.  • Raw materials required are same as in emulsions.  • Very high long-term stability.  • Application versatility.  
Solid lipid nanoparticles (SLN) are basically sub-micron 
colloidal carriers that are mainly pf the composition of 
physiological lipids, which are dispersed in water or in an 
aqueous surfactant solution. These are between 50 and 
1000nm, size range. The lipid matrixes, used in SLN are 
made from physiological lipid that decreases the danger of 
acute and chronic toxicity. They render  controlled and 
targeted release of the incorporated drug, enhance stability 
of the formulation, avoid the use of organic solvents, help to 
enhance bioavailability, of encapsulated drug, they offer 
better reproducibility, by use of various methods of 
preparation, both hydrophilic and hydrophobic drugs, can be 
encapsulated in these SLN.  
MATERIALS: 
Nabumetone was   provided   as   gift   sample   from   Cipla 
Pharmaceuticals and Research Center, Patalganga, Navi 
Mumbai. Polymers and  excipients  such  as  Compritol 
ATO888 was obtained from  Colorcon Asia Pvt Ltd., Goa. 
Glyceryl Monostearate, Tween 80, Span 20 and Stearic acid 
were procured from Research Lab Fine Chem. Mumbai.  
METHODS: 
EXPERIMENTAL WORK   
Preformulation Studies  
A. Physical Appearance: Physical state, taste, odour and 
colour of the drug sample was observed. 
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B. Solubility: 
Solubility of drug was determined in Distilled water, 
methanol and Chloroform, Ethanol. 
C. Melting point determination:  
Melting point of Nabumetone was determined using capillary 
tube method. The drug was filled in small quantity into one 
side sealed capillary tube which was tied to thermometer at 
its mercury bulb. The thermometer was inserted into Thieles 
tube containing liquid paraffin in such a way that the upper 
open end of capillary tube remain above the oil layer. The 
side arm of Thieles tube was then heated with burner till 
solid drug melts, and the melting temperature was noted. 
D. Partition Coefficient 
Determination of partition coefficient was done by shake 
flask method. 
Preparation:  
N-Octanol: The determination of the partition coefficient 
was carried out with high purity analytical grade reagent. 
Water: Distilled water was used.  
Procedure: 
 10mg of drug was added to 25 ml of distilled water and 25 
ml of n- octanol. It was shaken separately for half an hour. 
Both phases were then mixed together in a separating funnel 
and shaken for 4 hrs (on orbital shaker and allowed those to 
stand to get phase separated). 
Calibration curve of Nabumetone 
Standard graph of Nabumetone 
A precise, sensitive and accurate method for Nabumetone 
estimation was developed by using UV visible 
spectrophotometer 
Determination of wavelength of Nabumetone 
Accurate quantity of 10 mg of drug was weighed and 
transferred to 100 ml volumetric flasks then add 10 ml of 
methanol and dissolve drug completely; the volume was 
adjusted up to 100 ml with methanol to get stock solution, 
further stock solution was diluted suitably to get 10 µg/ml 
solution, which was analysed by UV-visible double beam spectrophotometer against methanol as a blank to confirm λ 
max of Nabumetone. UV spectrum was recorded using UV–
visible spectrophotometer with 1 cm quartz cells   (UV-1700 
Shimadzu). 
Preparation of standard Curve of Nabumetonein 
methanol A 10μg/ml stock solution of Nabumetone was prepared. 
Then aliquots of  0.2, 0.4, .0.6, 0.8,  and 1.0 ml of above 
solution in five different 10 ml volumetric flask and volume 
up to 10 ml with methanol were made. Absorbance of series 
of solution was taken and a graph of absorbance vs. 
concentration was plotted and was found to be linear over a range of 2 to 10μg/ml indicating its compliance with Beer’s 
law. 
The Linear Regression Analysis:  
The linear regression analysis was done on Absorbance 
points. A straight line equation (y = mx + c) was generated to 
facilitate the calculation of amount of drug. 
F) FT-IR spectrum: 
The drug and Compritol ATO 888 was subjected to FT-IR 
studies for the purpose of characterization. The scanning was 
performed between 4000 cm-1to 400cm-1 range. (JASCO 
4100, Japan)  
G) Differential Scanning Calorimetry (DSC):  
DSC studies of pure Nabumetone, Compritol ATO 888, were 
carried out. Accurately weighed samples were carefully 
added in DSC aluminum cup and heating curves were 
recorded in temperature range of 40–280 oC at a heating rate 
of 10oC/min under inert atmosphere. The study was carried 
out using Differential Scanning Calorimeter. (DSC 60 
Shimadzu, Japan) 
H) X-ray diffraction study  
XRD study was performed to analyse crystalline or 
amorphous nature of the excipients and drug. X-ray powder 
diffraction studies of pure Nabumetone, Compritol ATO 888 
were carried out using Advance X-ray Diffractometer 
(Bruker AXS D8 Advance XRD, Germany).  
Solubility Studies:  
Solubility study of Nabumetone in different lipids and 
surfactants:   
Solubility of drug must be quantified in each of the excipient 
used for preparation of SLNs. This quantification helped in 
determination of the loading dose of final dosage form. 
Besides this, selection of the specific component becomes 
easy after comparative analysis of drug solubility in different 
solvent. 
Solubility study of Nabumetone in different lipids  
Solubility of the drug in a lipid is a key factor to achieve high 
entrapment of the drug into the lipid matrix. Therefore, 
solubility of drug in various lipids was determined in order 
to determine the lipid having maximum potential to 
solubilize the drug.   
Procedure:  
Weighed amount of lipid (100 mg) was added to a glass vial. 
Drug was added to the vial in gradually increasing amount. 
The above mixture was heated to a temperature above 5–10°C of the lipid’s melting point. A transparent solution of 
the drug into the melted lipid indicated solubilisation of the 
drug into the lipid melt. This serves as an end point. The 
amount of drug added was calculated. 
Solubility study of Nabumetone in different surfactants   
Procedure:  
Solubility studies were conducted by adding an excess 
amount of Nabumetone in a vial containing 1 ml of the 
surfactant separately. The mixture was mixed manually for 
30 min. After that all mixtures were sonicated for 30 min. 
Then these mixtures were shaken using orbital shaker for 6 
hrs. The equilibrated sample was centrifuged at 11000 rpm 
for 30 min. The undissolved Nabumetone settles down at the 
bottom. The supernatant was taken out and diluted with 
methanol for quantification of by UV spectrophotometer at λ 
max of drug. 
Table No. 1: Different lipids and surfactant used for 
Solubility study 
Sr.no Lipids  Surfactants 
1 Glyceryl 
Monostearate 
Tween 60 
2 Compritol ATO 888 Tween 80 
3 Stearic acid Span 20 
4 Transcutol Labrafill 
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Formulation of Nabumetone loaded Solid lipid 
nanoparticles 
SLNs were prepared by hot homogenization technique and 
Ultrasonication technique which requires two immiscible 
phases Oil and aqueous phase with an emulsifier which helps 
in formation of an emulsion by reducing the interfacial 
tension. 
Method of Preparation of Nabumetone loaded Solid lipid 
nanoparticles hot homogenization technique and 
Ultrasonication technique (10,11,12)  
SLNs were also prepared by ultra-sonication method. For 
smaller particle size, combination of both ultrasonication and 
high speed homogenization is required. Drug was added to 
hot lipid melt. Hot aqueous phase was added to the hot lipid 
melt, emulsified by probe sonicator or by using high speed 
stirrer. Pre-emulsion was formed, sonicated using probe 
sonicator, o/w nanoemulsion was formed which was filtered 
to obtain SLNs. 
Optimization of formulation parameters and process 
variables for preparation of Nabumetone loaded SLNs 
Hot homogenization followed by Ultrasonication method 
The Box- Behnken design for Stirring speed, Stirring time & 
surfactant Tween 80 with 3 factors, 3 level and 17 runs was 
selected for optimization study separately and design expert 
10 software was used. The independent variables selected 
were stirring speed X1, Stirring time X2 & surfactant 
concentration X3and dependent variables were particle size 
(Y1), entrapment efficiency in percentage (Y2) with high, 
medium and low level and formulated as per Table No. 2. 
Optimization was performed to find out the level of 
independent variables that would yield a minimum value of 
the particle size (Y1), maximum value of entrapment 
efficiency (Y2) after optimization, the results were 
compared.
 
Table No.2: Independent variables and their corresponding levels of Nabumetone loaded SLN preparation for Box-
Behnken design 
 
Variables 
Levels     
-1 0 +1 
Stirring speed (rpm) 1200 1350 1500 
Stirring time (Hour) 3 4 5 
Surfactant concentration (ml) 0.5 1 1.5 
 
Table No. 3: Formulation table for the preparation of Nabumetone loaded SLN preparation 
Batch no. Factor 1 
Stirring rate 
(RPM) 
Factor 2 
Stirring time  
(Hours) 
Factor 3 
Concentration Of   surfactant 
(ml) 
1 0 -1 +1 
2 -1 0 -1 
3 0 0 0 
4 +1 0 -1 
5 -1 0 +1 
6 0 -1 -1 
7 0 +1 -1 
8 -1 -1 0 
9 0 +1 +1 
10 0 0 0 
11 0 0 0 
12 +1 -1 0 
13 0 0 0 
14 +1 0 +1 
15 +1 +1 0 
16 0 0 0 
17 -1 +1 0 
 
Characterization of Nabumetone loaded solid lipid 
nanoparticles  
Evaluation of batches for optimization  
1. Physical Appearance: The prepared Nabumetone SLNs 
were inspected for the colour, homogeneity, consistency 
2. Particle size analysis 
 By Digital Microscope  
The particle size was determined using an optical 
microscope with software (Pixel Pro). The average particle 
size was expressed in terms of nm. SLNs were mounted on 
slide and placed over stage of micrometer the software 
(Pixel Pro) for image analysis of nanoparticles. Each 
determination was carried out on a minimum of 100 
particles and their mean was reported. 
 By Zetasizer 1000 HS  
The formulation (0.1 ml) was dispersed in 50 ml of water in 
a volumetric flask and gently mixed by inverting the flask. 
Measurement was done using a Zetasizer 1000 HS (Malvern 
Instrument, UK). Light scattering was monitored  
3. Drug entrapment efficiency (13)  
The entrapment efficiency of SLN dispersion was 
determined by the centrifugation method. The SLN 
dispersion was centrifuged at 9000 rpm for 60 min in a 
cooling centrifuge to collect the supernatant liquid. The 
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collected 1ml liquid was filtered to measure the free drug 
concentration after suitable dilution with distilled water. 
The absorbance was measured at 261 nm in a UV 
Spectrophotometer to calculate the entrapment efficiency 
using following formula: 
Entrapment efficiency (%) = wt. of drug incorporated / wt. 
of drug initially taken x 100 
4. In vitro analysis 
In-vitro release studies were performed using artificial 
cellophane membrane (Molecular weight 12000). For this 
experiment a vertical Franz diffusion cell was used. The 
artificial membrane was securely placed between the two 
halves of the diffusion cell. The receptor compartment 
contains phosphate buffer (pH 7.4), its temperature 
maintained at 37±0.5ºC and stirred continuously using 
magnetic stirrer. A predetermined amount of Nabumetone 
loaded SLN containing 10 mg of Nabumetone was placed on 
the donor side. One ml of the sample was withdrawn from 
the receptor compartment at definite time intervals and 
replaced with equal volume of fresh receptor fluid. The 
aliquots were suitably diluted with the receptor medium and 
analysed by UV spectrophotometer. Measurements were 
done in triplicate and their means were reported.   
5. Scanning electron microscopy (14,15)   
Surface morphology of particles was studied with scanning 
electron microscopy (SEM). SLNs were mounted on double-
faced adhesive tape and coated with a thin gold–palladium 
layer by sputter-coated unit and analysed with scanning 
electron microscope (JEOL JSM-6360 A). 
6. FT-IR spectrum: 
The SLNs optimized formulation was subjected to FT-IR 
studies for the purpose of characterization. The scanning 
was performed between 4000 cm-1to 400cm-1 range. 
(JASCO 4100, Japan) (16) 
7. Differential Scanning Calorimetry (DSC): 
DSC studies of the lyophilized SLN powder were carried out. 
Accurately weighed samples were carefully added in DSC 
aluminium cup and heating curves were recorded in 
temperature range of 40–280 ºC at a heating rate of 
10ºC/min under inert atmosphere. The study was carried 
out using Differential Scanning Calorimeter. (DSC 60 
Shimadzu, Japan) 
8. Zeta potential measurement   
Zeta potential distribution was determined by using a 
zetasizer (Horiba, Japan SZ 100). One mg of freeze dried 
Nabumetone SLN was dispersed in distilled water. To 
prevent the agglomeration, the dispersed solution was 
placed for 5 min in ultra sonicator bath.  Then the sample 
was taken in the glass cuvette and zeta potential was 
measured in range from -200 to +200mv. 
9. pH measurement  
The pH value of optimized Nabumetone SLN was measured 
by pH meter (Equip-tronics) 
10. Ex-vivo drug deposition study: 
The Ex-vivo diffusion study was performed on excised Goat 
skin. The abdominal skin of goat was shaved, carefully 
placed on the Franz diffusion cell with the epidermal side 
facing the donor compartment and the dermal side in 
contact with the receptor solution. Sample was applied to 
donor compartment. The receptor compartment contains 
phosphate buffer (pH 7.4), its temperature maintained at 
37±0.5ºC and stirred continuously using magnetic stirrer. A 
predetermined amount of Nabumetone loaded SLN 
containing 10 mg of Nabumetone was placed on the donor 
side. One ml of the sample was withdrawn from the receptor 
compartment at definite time intervals and replaced with 
equal volume of fresh receptor fluid. The aliquots were 
suitably diluted with the receptor medium and analysed by 
UV spectrophotometer. Measurements were done in 
triplicate and their means were reported (17). 
 
Figure No.2: Franz diffusion cell apparatus 
Carrageenan induced rat paw oedema 
This study was done on Wistar rats. 18 rats were selected of 
250gms. Three groups were utilized, stating control, test and 
standard, with 6 rats in each group. They were kept on 
fasting condition for 24 hours. Next day, fresh solution of 1% 
carageenan was prepared and further used for the study. 
The rats were labelled properly, and their paw size was 
measured using vernier calliper. The paw was marked, and 
the left paw was injected with carageenan solution using 
tuberculin syringe, and again the paw volume was measured 
using vernier calliper. The test group was drug loaded solid 
lipid nanoparticle gel was applied. To the standard group, 
the marketed gel was applied, and after every hour the paw 
volume was measured. Total inhibition was calculated (18,19). 
The percentage (%) inhibition of edema is calculated using 
the formula 
Percentage Inhibition = 
Vc – Vt/ Vt X100 
Where, Vc is paw volume in control; Vt is paw volume in test 
drug 
RESULTS AND DISCUSSION 
Preformulation of Nabumetone: 
A.  Physical Appearance:  
Nabumetone was checked visually for colour, odour and 
nature. The results are summarized in Table No. 4. 
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Table No.4:  Physicochemical properties of Nabumetone 
Sr.No. Parameters Observation 
1 Physical state  Crystalline powder form 
2 Colour White 
3 Odour Typical odour 
 
B. Solubility:  
Solubility of drug in various solvent was found to be as 
shown in Table No. 5. 
Table No. 5: Solubility studies of Nabumetone 
Sr.No. Solvent  Solubility 
1 Distilled water Insoluble 
2 Ethanol Slightly soluble 
3 Methanol soluble 
 
C. Melting point:  
Melting point of drug was observed at 80-81oC 
D. Partition Coefficient: 
Partition coefficient (n-octanol/water) of Nabumetone was 
determined by shake flask method. Partition coefficient (log 
P) was found to be 3.08 
E. Calibration curve of Nabumetone:  
Nabumetone solution which was scanned in the range of 400 nm to 200 nm showed maximum absorption (λ max) at 261 
nm. Absorbance of prepared solution was measured at 261 
nm using UV spectrophotometer. Drug followed Beers and Lamberts law in the range of 2 to 10μg/ml. Calibration curve 
and related data are given in the Table No. 6 and Figure No.3.  
Table No.6: Absorbance data of Nabumetone in Methanol 
Sr.no. Concentration (ug/ml) Absorbance 
1 2 0.207 
2 4 0.410 
3 6 0.634 
4 8 0.874 
5 10 1.102 
 
 
Figure No. 3: Calibration curve of Nabumetone
 
 
F) FT-IR spectrum: 
 
Figure No. 4: FT-IR spectrum of Nabumetone 
Table No.7: FT-IR spectrum interpretation of Nabumetone 
Sr.no. Wavelength cm-1 Functional group 
1 2950-2840 -C-H stretching 
2 1600-1400 C=C aromatic 
3 1400-1365 CH3 bend 
4 1200-1020 O-CH3 ether 
 
y = 0.2254x - 0.0308 
R² = 0.9992 
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Figure No. 5: FT-IR spectrum of Compritol ATO 888 
Table No. 5: FT-IR spectrum interpretation of Compritol ATO 888 
Compritol ATO 888 
Sr no. Wavelength (cm-1) Functional group 
1 3650-3100 (cm-1) C =O  
O 
2 700 -1500 (cm-1) (CH2)2 
 
DSC Study 
 
Figure No. 6: DSC Spectrum of Nabumetone 
 
Figure No. 7: DSC Spectrum of Compritol ATO 888 
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Figure no 6 and 7 shows the differential scanning calorimetry (DSC) profile of, Nabumetone and Compritol ATO 888.  The Nabumetone and Compritol ATO 888 showed sharp endothermic peak at 82.37 and 73.93 ◦C, respectively, corresponding 
to their melting temperatures. Sharp peak of drug showed purified form of drug. 
   X-ray diffraction study 
 
Figure No. 8: X-ray diffraction of Nabumetone 
 Figure No.8  and 9 shows the X-ray diffraction profile of Nabumetone and Compritol .The X-ray diffractogram of Nabumetone 
indicated high intensity of peak which indicated crystalline nature of peak  
 
Figure No. 9:X-ray diffraction of Compritol ATO 888 
 
Solubility study of Nabumetone in different lipids and 
surfactants: Lipid screening: 
Lipid based formulation can be used to increase drug 
absorption by increasing solubilisation, enhancing 
permeability, reducing drug metabolism. The pharmaceutical 
and pharmacological implication were evaluated the drug-
lipid miscibility in solid lipid nanoparticle.  
The solubility of Nabumetone in various pharmaceutically 
accepted lipids was determined  as shown in Table No. 6 and 
Figure No. 10, in order to choose the lipid for Nabumetone 
loaded SLN.  
Table No. 6: Solubility study of Nabumetone in different 
lipid 
Lipids Concentration (mg/ml ) 
Glyceryl monostearate 3.10 
Compritol ATO 88 47.90 
Sterric acid 15.45 
Transcutol 20.13 
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Figure No. 10: Solubility study of Nabumetone in different lipids 
 
The solubility of Nabumetone was higher in compritol ATO 
888. So, on the basis of solubility compritol ATO 888 was 
selected for the further formulation. Higher concentration of 
compritol ATO 888 shows higher entrapment efficiency of 
drug, but excess amount of lipid retard the drug release 
through SLNs. The lower concentration of lipid shows lower 
entrapment efficiency of drug. Therefore the optimized 
quantity was used for the formulation according to particle 
size, entrapment efficiency and dug release. 
Selection of surfactant and co-surfactant:  
The miscibility of a drug and excipients was dependent upon 
the intermolecular interactions formed between the drug 
(solute) and excipients (solvent). 
The solubility of Nabumetone was determined in various 
surfactants is as shown in Table No. 7 and Figure No. 11. 
    
 
Figure No. 11: Solubility study of Nabumetone in 
different Surfactants 
 
 
Table No. 7: Solubility study of Nabumetone in different 
surfactant 
Surfactant Solubility(mg/ml) 
Tween 60 13.10 
Span 80 15 
Tween 80 24 
Tween 20 9.08 
Span 20 12 
 
The different types of surfactant Tween 80, Span 80, Tween 
60, Tween 20, Span 20 were used as surfactant. Depending 
upon the solubility of drug in the surfactant, Tween 80 was 
selected as surfactant. The type and concentration of 
surfactant affect the particle size, entrapment efficiency as 
well as stability of nanoparticles. Low concentration tween 
80 will not be sufficient to give sphericity to the 
nanoparticles resulting into increased particle size and form 
aggregative mass of nanoparticles. High concentration of 
Tween 80 may lead to bridging between nanoparticles and 
also cause foaming. So, the optimum quantity was selected 
according to particle size, entrapment efficiency and drug 
release. 
Formulation of Nabumetone loaded Solid lipid 
nanoparticles  
SLNs were prepared by hot homogenization technique and 
Ultrasonication technique which requires two immiscible 
phases Oil and aqueous phase with an emulsifier which 
helps in formation of an emulsion by reducing the interfacial 
tension. All 17 batches were formulated separately 
according to Box- Behnken design by using combination of 
ultra-sonication followed by homogenization.  
Optimization of Nabumetone loaded SLNs by using Box-
Behnken design 
Box-Behnken design was used to study the effect 
concentration of surfactant, stirring time & stirring speed on 
different parameter like entrapment efficiency, particle size 
and drug release, as depicted in Table No. 8. 
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Table no 8: Box Behnken design for optimization of Nabumetone loaded SLNs 
Sr. no Factor 1 Factor 2 Factor 3 Response 1 Response 2 
 A stirring speed B stirring time C surfactant Entrapment efficiency Particle size 
 (RPM) (Hrs) (ml) (%) (nm) 
1 1350 3 1.5 87.43 30.54 
2 1200 4 0.5 75.41 24.21 
3 1350 4 1 90.57 26.62 
4 1500 4 0.5 86.43 24.50 
5 1200 4 1.5 89.84 11.34 
6 1350 3 0.5 79.68 34.02 
7 1350 5 0.5 80.25 39.54 
8 1200 3 1 78.27 21.70 
9 1350 5 1.5 91.25 23.25 
10 1350 4 1 90.57 26.62 
11 1350 4 1 90.57 26.62 
12 1500 3 1 92.85 26.23 
13 1350 4 1 90.57 26.62 
14 1500 4 1.5 94.40 16.54 
15 1500 5 1 88.49 18.54 
16 1350 4 1 90.57 26.62 
17 1200 5 1 85.12 19.62 
 
Optimization of stirring speed and stirring time  
Speed and time for stirring was evaluated by particle size. It 
was seen that the particle size lowest at speed 1500 rpm for 
4 hrs. The effect of stirring speed and time on particle size 
was evaluated for different batches. Firstly, the Nabumetone 
SLNs was analysed at 1000, 1500 and 2000 rpm for 1hrs. 
After it the optimization of stirring time was carried out for 
time 1, 2 and 3 hrs. Larger particles were obtained at low 
stirring rates and time, whereas smaller particle sizes were 
observed at high stirring rates and time. But highest stirring 
rate larger particles were observed. Focusing on minimal 
particle size the optimum stirring condition for SLNs was 
found at stirring speed 1500 rpm time for 4hrs. The particle 
size increases with increasing in stirring rate and time, may 
be due to the highest kinetic energy of the system with 
higher agitation forces for prolonged periods. Because of this 
energy smaller particle and even larger particle have 
tendency to bind together with each other and surrounding 
particles by overcoming the interfacial energy barrier.   
Sonication time (Ultra-sonication method) 
Sonication time was increased (40 min) it showed decreased 
in particle size but after some time SLNs particles go 
breakdown and formed irregular shape particles and also 
decreased the entrapment efficiency of drug. Sonication time 
decreased (5 min) it formed aggregative mass of Compritol 
ATO 888 and increased particle size. Sonication times 
(10min) were selected for optimization study.  
Characterization of Nabumetone loaded solid lipid 
nanoparticles  
Evaluation of batches for optimization 
1. Physical Appearance:   
The prepared Nabumetone SLNs were homogeneous, white, 
and consistent. 
2. Particle size:
 
Table No. 9: ANOVA for responses surface (Particle size) 
Source 
Particle size (nm) 
p-value R-square 
Model(Quadratic) < 0.0001  
0.9873 
Significant 
A. Stirring speed 0.0250 
B. Stirring time 0.0080 
C. Concentration of surfactant < 0.0001 
 
For the particle size, the value of correlation (R2) was found 
to be 0.9873, indicating good fit of the model. P - Value for all 
the independent variable was less than 0.05 that means it 
has significant model terms. Low P- value was likely to be a 
meaningful addition to model because changes in the predictor’s value are related to changes in the response 
variable.  
The equation in terms of coded factors used to make 
predictions about the response of particle size for given level 
of each factor as mentioned below. The coded equation was 
useful for identifying the relative impact of the factor by 
comparing the factor coefficients. 
Final equation in terms of coded factor  
Particle size = 26.12+1.12*A-1.44*B-5.08*C - 1.40*AB -
1.23*AC + 3.20*BC -8.80 A2+3.80 B2+1.40 C2 
The equation in terms of coded factors can be used to make 
predictions about the response for given levels of each 
factor. By default, the high levels of the factors are coded as 
+1 and the low levels of the factors are coded as -1. The 
coded equation is useful for identifying the relative impact of 
the factors by comparing the factor coefficients. 
Final equation in terms of actual factor 
Particle size = -675.50125 + 1.09573 x Stirring speed -
1278500 x Stirring time -17.99500 x Surfactant 
concentration 
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The equation in terms of actual factors can be used to make 
predictions about the response forgiven levels of each factor. 
Here, the levels should be specified in the original units for 
each factor. This equation should not be used to determine 
the relative impact of each factor because the coefficients are 
scaled to accommodate the units of each factor and the 
intercepts not at the Centre of the design space.  
 
 
Figure no. 12: Optical microscopy of optimized batch (F14) of Nabumetone loaded SLN 
 
Figure No. 13: Contour plot for stirring speed and stirring time affecting on particle size 
 
Figure No. 14: 3D plot for stirring speed and stirring time affecting on particle size 
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Effect of Stirring speed and time on particle size:  
There is inverse relationship between homogenization speed 
and time. homogenization speed and time increase (9000 
rpm for10min) particle size was spherical but after some 
time particle get breakdown and form irregular shape 
particle, less entrapment of drug was observed. 
homogenization speed and time  (5000 rpm for 150min) the 
compritol ATO 888 form aggregate mass that increased in 
the particle size of SLNs The homogenization speed and time 
(6000 rpm 30min)showed higher entrapment efficiency and 
reduce particle size.  
Effect of surfactant concentration on particle size:  
According to Figure No.13 and 14, when concentration of 
surfactant increased, there is reduction in the particle size. 
This was to be expected, because a higher surfactant 
concentration will cover the surface of the lipid phase, 
resulting in smaller particle size. The presence of a sufficient 
amount of surfactant was proposed to help the solubilisation 
and stabilization of drug molecules within the lipid matrix 
and at the surface.  
The decrease in particle size at high surfactant concentration 
might be due to effective reduction in interfacial tension 
between the aqueous and lipid phases leading to the 
formation of emulsion. Higher surfactant concentration 
effectively stabilised the particle by forming a stearic barrier 
on the particle surface and thereby protect smaller particle 
and prevent their coalescence into bigger ones. 
 
 
Figure No. 15: Batch wise results of particle size 
The batch wise result of particle size was shown in Figure No.15, batch no F- 5 and F-14 showed lowest particle size while F -6 
and F-7 showed highest particle size.   
Entrapment efficiency:   
Table No. 10: ANOVA for responses surface (Entrapment Efficiency) 
Source Drug Entrapment Efficiency (%) 
p-value R-square 
Model(Quadratic) < 0.0001  
 
0.9943 
Significant 
A. Stirring speed < 0.0001 
B. Stirring time 0.0064 
C. Concentration of surfactant < 0.0001 
 
 
For the entrapment efficiency, the value of the correlation 
coefficient (R2) was found to be 0.9943 indicating good fit of 
the model. P value for all the independent variables was 
below 0.05 that means it has significant model terms. The 
equation in terms of coded factors can be used to make 
prediction about the response for given levels of each factor. 
The coded equation is useful for identifying the relative 
impact of the factors by comparing the factor coefficient. 
Final equation in terms of coded factors: 
Entrapment efficiency = 90.57+4.19 *A +0.8600 *B +5.14 *C -
2.80 *AB -1.62 *AC +0.8125*BC -1.05A2-3.13 B2-2.79 C2 
It shows that as the concentration of surfactant increases, EE 
decreases. This may be due to increase in the partition of the 
drug from internal to external phase of the medium at the 
high concentration of surfactant. 
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Figure No. 16: Counter plot for the effect stirring speed &stirring time on Entrapment efficiency 
` 
Figure No. 17: 3D plot for the effect stirring speed & stirring time on  Entrapment efficiency 
 
From the response 3D plot for the EE (Figure no.17), it can 
be seen that as the concentration of surfactant increases, EE 
decreases. This may be due to decreases in the particle size. 
It may also be due to increases in the partition of the drug 
from internal to external phase of the medium at the high 
concentration of surfactant.  
 
Effect of stirring speed and time on entrapment 
efficiency  
The entrapment efficiency was directly proportional to 
stirring speed. And increase in stirring speed a vigorous 
uniform and rapid division of nanoparticle this may have 
less chances of coalescing into bigger particle. This leads to 
decrease in particle size with increased in stirring rate as 
shown in Figure no.18.  
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Figure No. 18: Batch wise results of entrapment efficiency 
In vitro drug release study 
The in-vitro release of Nabumetone SLN was varied in amount according to concentration of emulsifying agents used in 
formulations it was concluded that SLN showed better drug release within 7 hours (Figure no. 19.). 
 
Figure No. 19:  Batch wise results of in vitro drug release 
 
Evaluation for optimized of Nabumetone loaded SLN 
Batch F-14 shows smaller particle size, higher entrapment 
efficiency and more drug release due of higher concentration 
of surfactant. So, batch F-14 was finally optimized and 
further used for the formulation and evaluation 
1. Particle size:   
By Digital Microscope:   
The optimized batch was subjected to particle size. The 
particle size was approximately 16.54.nm (Figure No 20.) 
which is depends on surfactant concentration stirring rate 
and stirring time.   
 
Figure No.20: Optical microscopy of optimized 
formulation (F14)
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2. Dilution test: 
 It was confirmed that W/O type of emulsion was formed and following table showed the observation and interference. 
Table No 11: Observation for dilution test 
Test no.  Observation Interference 
1. Emulsion did not break   O/W type of emulsion was not formed 
2. Emulsion break W/O type of emulsion was formed 
 
3. pH:  
The pH of optimized formulation of Nabumetone loaded 
SLNs was found to be 6 and pH of the human skin is in the 
range of 4 to 7, so it was concluded that prepared 
formulation was compatible with human skin. 
4. IR and DSC spectra: 
The result of optimized formulation Figure No. 21 and 22 
was indicated that there was not formation of new peak so 
the drug and excipients were compatible with each other 
and revealed that Nabumetone was successfully incorporate 
into the Nabumetone SLNs.   
 
 
 
Figure No. 21: FTIR spectra of optimized batch of Nabumetone SLN 
 
Figure No. 22: DSC spectra of optimized batch (14) of Nabumetone SLN 
Zeta potential measurements: 
Zeta potential of SLN formulations were determined to 
observe net surface charge on SLN and surrounding system. 
Zeta potential of SLN was determine to understand the 
stability aspect and quality control measure. The magnitude 
of the zeta potential gives the indication of the potential 
stability of the colloidal system. If all the particles in 
suspension have large negative or positive zeta potential 
then they will tend to repel each other and there will be no 
tendency for the particles to come together. However, if the 
particles have low zeta potential values then particles 
coming together and flocculating. The general dividing line 
between stable and unstable suspension is generally taken at 
either -30 or +30 mv. Particles with zeta potentials more 
positive than +30mv or more negative than -30mv are 
normally considered stable. The variation of zeta potential 
related with nature of dispersion medium. 
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Figure No. 23: Zeta potential of optimized batch (F14) 
 
Figure No. 24: SEM of optimized batch (F14) 
 
Preparation of SLNs based gel: 
The SLNs dispersion was converted into gel carrier system 
using gelling agents such as Polycarbophil, Xanthan gum and 
Carbopol (different grades 940, 934). Gelling agent at various 
concentrations were dispersed under stirring in to the SLNs 
dispersion till they were uniformly mixed to form gel with 
suitable consistency In some cases, pH of dispersion was 
adjusted in between 5.5-6.5 by triethanolamine to form gel 
with good consistency. 
 Evaluation of gels 
A. Homogeneity 
All developed gels were tested for homogeneity by visual 
inspection after the gels have been set in container. They 
were tested for their appearance and presence of any 
aggregates. 
B. Physical evaluation 
Physical parameters such as colour and appearance were 
evaluated by physical inspection. 
C. pH measurement 
pH of the gel was measured by using pH meter (Remi, 
INDIA).pH of formulation observed in the range of 6.8-
7.1.which indicated prepared formulation compatible with 
skin. pH of optimized batch (F14) was found to be 6.8.  
D. Viscosity and Rheological studies 
The viscosity of gels was determined by using Brookfield 
viscometer. The gel was placed in the sample holder and the 
suitable spindle selected was lowered perpendicularly into 
the sample. The spindle was attached to viscometer and then 
it was allowed to rotate at a constant optimum speed at room 
temperature. The readings were noted after 2 minutes. The 
result of viscosity showed that increasing concentration of 
carbopol 940 from 0.25٪ to 0.5٪ viscosity was found to 
increase. It was observed that formulation were found to be 
liquid form before adding triethanolamine addition of 
triethanolamine cause increase in viscosity which transform 
liquid phaseto gel such result observed due to ionic 
repulsion of carboxylate group and the polymer become stiff 
and rigid there by increase the viscosity of formulation. 
Viscosity of optimized batch (F14) was found to be 2618cps. 
E. Spreadability 
It observed that increasing the concentration of the Carbopol 
940 was associated with the decrease in spread ability. As 
the Carbopol concentration increased viscosity and gel 
strength of formulation was found increase and spread 
ability was decrease spread ability play important role in 
patient compliance and help in uniform application of gel to 
the skin. A good gel takes less time to spread and will have 
good spread ability. 
Spread ability of optimized batch (F14) was found to be 16.3 
(Gm.cm/sec).
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Carrageenan induced rat paw edema results 
 
Figure 25: Effect of % inhibition of paw edema in carrageenan induced rat paw edema  
The anti-inflammatory action of the solid lipid nanoparticles 
was observed and it depicted the significant inhibition, when 
compared to the carrageenan induced edema, and was 
comparable to that of the standard.  
CONCLUSION: 
Thus, the study of inclusion of Nabumetone in SLN, by use of 
optimization Box-Benhken design showed the prolonged 
action, with good particle size and entrapment efficiency.  
The anti-inflammatory study also showed inhibition in the 
edema, when compared to the standard. 
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